*ST赛隆：产品“注射用尼可地尔”取得注册证

Group 1 - The core point of the article is that *ST Sailong has received approval from the National Medical Products Administration for its injectable Nicorandil product, which is a significant development for the company [1] - As of January to June 2025, *ST Sailong's revenue composition is as follows: 59.82% from the pharmaceutical manufacturing sector, 39.78% from the electronics sector, and 0.4% from other businesses [1] - The current market capitalization of *ST Sailong is 2.3 billion yuan [1]